Con: Dialy- and continuous renal replacement (CRRT) trauma during renal replacement therapy: Still under-recognized but on the way to better diagnostic understanding and prevention

Nephrology Dialysis Transplantation

Volumn 28, Issue 11, 2013, Pages 2723-2728

  Honoré, Patrick M ^a   Jacobs, Rita ^a   Joannes Boyau, Olivier ^b   De Waele, Elisabeth ^a   Van Gorp, Viola ^a   Boer, Willem ^c   Spapen, Herbert D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

AKI; Antibiotic dosing; CRRT trauma; Dialytrauma

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; COLISTIN; CYTOKINE; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTINUOUS RENAL REPLACEMENT THERAPY; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; HYPOPHOSPHATEMIA; INTENSIVE CARE UNIT; KIDNEY BLOOD FLOW; KIDNEY INJURY; LOADING DRUG DOSE; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT RESPONSE;

AKI; ANTIBIOTIC DOSING; CRRT-TRAUMA; DIALY-TRAUMA;

ACUTE KIDNEY INJURY; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY;

EID: 84890077914     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft086     Document Type: Article

References (47)

1. Maynar-Moliner J, Sanchez-Izquierdo-Riera JA, Herrera-Gutierrez M. Renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 1960-1962
2. Maynar-Moliner JM, Honore PM, Sanchez-Izquierdo JA et al. Handling RRT-related adverse effects in ICU patients: the Dialytrauma concept. Blood Purif 2012; 34: 177-185
3. Palevsky PM, Zhang JH, O'Connor TZ et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20
4. Bellomo R, Cass A, Cole L et al. Intensity of continuous renalreplacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-1638
5. Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010; 6: 521-529
6. Ronco C, Cruz D, Oudemans van Straaten H et al. Dialysis dose in acute kidney injury: no time for therapeutic nihilism-a critical appraisal of the Acute Renal Failure Trial Network study. Crit Care 2008; 12: 308
7. Honore PM, Jacobs R, Joannes-Boyau O et al. Septic AKI in ICU patients. Diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments. Ann Intensive Care 2011; 1: 32
8. Joannes-Boyau O, Honoré PM, Bagshaw SM et al. The IVOIRE Study: description of the methodology and the design used. Electronic Supplemental Material. Intensive Care Med 2013; Second Revised Submission.
9. Munoz-Price LS, Dezfulian C, Wyckoff M et al. Effectiveness of stepwise interventions targeted to decrease central catheterassociated bloodstream infections. Crit Care Med 2012; 40: 1464-1469
10. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120: 179-184
11. Honore PM, Jacobs R, Spapen HD. Use of antifungal drugs during continuous hemofiltration therapies. Annu Updat Intensive Care Emerg Med 2012; 337-347
12. Roberts DM, Roberts JA, Roberts MS et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40: 1523-1528
13. Taccone FS, de Backer D, Laterre PF et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37: 531-535
14. Spapen HD, Janssen van Doorn K, Diltoer M et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011; 1: 26
15. Jamal JA, Economou CJ, Lipman J et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18: 460-471
16. Choi G, Gomersall CD, Tian Q et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37: 2268-2282
17. Vincent JL. Critical care nephrology: a multidisciplinary approach. Contrib Nephrol 2007; 156: 24-31
18. Honoré PM, Joannes-Boyau O, Gressens B. CRRT technology and logistics: is there a role for a medical emergency team in CRRT? Contrib Nephrol 2007; 156: 354-364
19. De Becker W. Starting up a continuous renal replacement therapy program on ICU. Contrib Nephrol 2007; 156: 185-190
20. Yee J. Newphrologist: the intensive care kidney specialist. Adv Chronic Kidney Dis 2013; 20: 1-3
21. Cerdá J, Tolwani AJ, Warnock DG. Critical care nephrology: management of acid-base disorders with CRRT. Kidney Int 2012; 82: 9-18
22. Ricci Z, Ronco C, D'Amico G et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006; 21: 690-696
23. Honore PM, Jacobs R, Spapen HD. Antibiotic adsorption on CRRT membranes. Relevance and impact on antibiotic dosing in critically ill patients. Annu Updat Intensive Care Emerg Med 2013; 33: 123-131
24. Alsumrain MH, Jawad SA, Imran NB et al. Association of hypophosphatemia with failure-to-wean from mechanical ventilation. Ann Clin Lab Sci 2010; 40: 144-148
25. Troyanov S, Geadah D, Ghannoum M et al. Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy. Intensive Care Med 2004; 30: 1662-1665
26. Tolwani AJ, Campbell RC, Stofan BS et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008; 19: 1233-1238
27. Polderman KH, Schreuder WO, Strack van Schijndel RJ et al. Hypernatremia in the intensive care unit: an indicator of quality of care? Crit Care Med 1999; 27: 1105-1108
28. Ratanarat R, Brendolan A, Volker G et al. Phosphate kinetics during different dialysis modalities. Blood Purif 2005; 23: 83-90
29. Morabito S, Pistolesi V, Maggiore U et al. Pharmacokinetics of antibiotics in continuous renal replacement therapies (CRRT). G Ital Nefrol 2012; 29: 425-444
30. Van Wert R, Friedrich JO, Scales DC et al. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med 2010; 38: 1360-1369
31. Zhang Z, Xu X, Zhu H. Intensive-vs less-intensive-dose continuous renal replacement therapy for the intensive care unitrelated acute kidney injury: a meta-analysis and systematic review. J Crit Care 2010; 8: 595-600
32. Cantaluppi V, Medital D, Honoré PM et al. Biological effects of High Volume Hemofiltration (HVHF) on endothelial and tubular cell alterations by septic plasma. An IVOIRE Substudy. [Abstract ]16th International Conference on CRRT. San Diego, 22-25 Feb 2011
33. Honoré PM, Jacobs R, Boer W et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 2012; 33: 44-51
34. Taccone FS, Laterre PF, Spapen HD et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53
35. Spapen H, Jacobs R, Van Gorp V et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14
36. Radej J, Krouzeckt A, Stehlik P et al. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous veno-venous hemofiltration. Ther Drug Monit 2011; 33: 393-397
37. Semel ME, Resch S, Haynes AB et al. Adopting a surgical safety checklist could save money and improve the quality of care in US Hospitals. Health Aff (Millwood) 2010; 29: 1593-1599
38. Kielstein JT, Schiffer M, Hafer C. Back to the future: extended dialysis for treatment of acute kidney injury in the intensive care unit. J Nephrol 2010; 23: 494-501.
39. Schwenger V, Weigand MA, Hoffmann O et al. Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury-a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012; 16: R140.
40. Kielstein JT, Burkhardt O. Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotechnol 2011: 12: 2015-9.
41. Jones SL, Devonald MA. How acute kidney injury is investigated and managed in UK intensive care units-a survey of current practice. Nephrol Dial Transplant 2013.
42. Du B, An Y, Kang Y et al. Characteristics of critically ill patients in ICUs in Mainland China. Crit Care Med 2013; 41: 84-92.
43. Clajus C, Kuhn-Velten WN, Schmidt JJ et al. Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of underdosing using current dosing recommendations. BMC Pharmacol Toxicol 2013; 14: 19.
44. Kielstein JT, Heiden A, Beutel G et al. Renal function and survival in 200 patients undergoing ECMO therapy. Nephrol Dial Transplant 2012; 12: 15.
45. Eyler RF, Heung M, Pleva M et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy 2012; 32: 1061-9.
46. Kielstein JT, David S. Magnesium: the 'earth cure' of AKI? Nephrol Dial Transplant 2013; 28: 785-7.
47. Hetzel GR, Schmitz M, Wissing H et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-9.